Carillon Tower Advisers Inc. raised its position in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 0.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,496 shares of the specialty pharmaceutical company’s stock after buying an additional 300 shares during the period. Carillon Tower Advisers Inc.’s holdings in Eagle Pharmaceuticals were worth $2,701,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Quantamental Technologies LLC bought a new position in shares of Eagle Pharmaceuticals during the first quarter worth about $79,000. LS Investment Advisors LLC lifted its position in shares of Eagle Pharmaceuticals by 97.9% during the fourth quarter. LS Investment Advisors LLC now owns 2,157 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 1,067 shares during the last quarter. Flinton Capital Management LLC lifted its position in shares of Eagle Pharmaceuticals by 23.9% during the fourth quarter. Flinton Capital Management LLC now owns 2,464 shares of the specialty pharmaceutical company’s stock worth $99,000 after purchasing an additional 476 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Eagle Pharmaceuticals by 545.7% during the first quarter. BNP Paribas Arbitrage SA now owns 2,602 shares of the specialty pharmaceutical company’s stock worth $131,000 after purchasing an additional 2,199 shares during the last quarter. Finally, Neuburgh Advisers LLC lifted its position in shares of Eagle Pharmaceuticals by 23.9% during the fourth quarter. Neuburgh Advisers LLC now owns 2,992 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 578 shares during the last quarter. 94.36% of the stock is owned by institutional investors.

Several equities analysts have recently commented on EGRX shares. ValuEngine raised shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Royal Bank of Canada set a $66.00 price objective on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, March 1st. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 5th. Cantor Fitzgerald reiterated a “hold” rating and set a $58.00 price objective on shares of Eagle Pharmaceuticals in a research note on Monday, April 15th. Finally, Mizuho reiterated a “hold” rating and set a $50.00 price objective on shares of Eagle Pharmaceuticals in a research note on Wednesday, April 24th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $65.17.

In related news, CEO Scott Tarriff sold 24,428 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $51.17, for a total transaction of $1,249,980.76. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Douglas L. Braunstein sold 159,223 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $56.81, for a total transaction of $9,045,458.63. The disclosure for this sale can be found here. Insiders sold 208,626 shares of company stock worth $11,547,936 in the last 90 days. 28.20% of the stock is owned by company insiders.

EGRX opened at $55.88 on Thursday. The stock has a market cap of $774.06 million, a P/E ratio of 26.74 and a beta of 1.67. Eagle Pharmaceuticals Inc has a fifty-two week low of $36.03 and a fifty-two week high of $85.66. The company has a current ratio of 4.12, a quick ratio of 3.89 and a debt-to-equity ratio of 0.21.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.28. Eagle Pharmaceuticals had a net margin of 17.67% and a return on equity of 21.38%. The firm had revenue of $49.80 million for the quarter, compared to analyst estimates of $47.03 million. During the same quarter in the prior year, the business earned $0.55 earnings per share. Eagle Pharmaceuticals’s quarterly revenue was up 6.9% on a year-over-year basis. Sell-side analysts predict that Eagle Pharmaceuticals Inc will post 1.75 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Carillon Tower Advisers Inc. Has $2.70 Million Holdings in Eagle Pharmaceuticals Inc (EGRX)” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2019/05/16/carillon-tower-advisers-inc-has-2-70-million-holdings-in-eagle-pharmaceuticals-inc-egrx.html.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Recommended Story: What is the 52-week high/low?

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.